No Detail Found!

Role of montelukast in preventing relapse in childhood idiopathic nephrotic syndrome: a quasi-experimental study

Author(s)
Hashim Raza Department of Pediatric Nephrology, The Children's Hospital and The Institute of Child Health, Multan, Pakistan
Muhammad Imran Department of Pediatric Nephrology, The Children's Hospital and The Institute of Child Health,Multan,Pakistan
Khuram Rashid Department of Pediatric Nephrology, The Children's Hospital and The Institute of Child Health,Multan,Pakistan
Shahid Ishaq Department of Pediatric Nephrology, The Children's Hospital and The Institute of Child Health,Multan,Pakistan
Waqas Shakir Department of Pediatric Medicine, The Children's Hospital and The Institute of Child Health,Multan,Pakistan
Mudasser Adnan Department of Pediatric Cardiology, The Children's Hospital and The Institute of Child Health,Multan,Pakistan
Abstract
OBJECTIVE: To study the role of montelukast in preventing relapses in childhood idiopathic steroid sensitive nephrotic syndrome (SSNS). METHODS: This quasi-experimental, open label study was conducted at Department of Paediatric Nephrology, The Children's Hospital and The Institute of Child Health, Multan, Pakistan. Total of 106 patients with firstepisode of nephrotic syndrome aged 1-10 years were enrolled from FebruaryMay 2019 and non-randomly assigned to Group-A & Group-B (53 patients in each group). All patients in both groups were started on prednisolone 2mg/kg single morning dose for 4-weeks as per institutional protocol. Group-A (Cases) also received montelukast 5 mg daily at bedtime for at least 12 months while Group-B (control) was not given montelukast. All patients were followed up for one year till May 2020 to monitor the response to treatment and evidence of relapse. Ten patients were excluded from final analysis due to loss to follow-up (n=3; 2 in Group-A and 1 in Group-B) or showing steroid resistance (n=7; 3 in Group-A and 4 in Group-B). RESULTS: Out of 96 children (48 each in Group-A & B), 58 (60.4%) were males. Mean age was 4.7±1.9 years and most of children (n=64; 66.7%), were aged between 2-6 years. Overall relapse rate of 35.4% (n=34/98) was observed, with 9/48 (18.8%) patients in Group-A compared to 25/48 (52.1%) patients in Group-B (p<0.001). Out of 34 patients with relapse, 20 (58.8%) were males and 14 (41.2%) were females. CONCLUSION: Montelukast showed significant efficacy in preventing relapse rate in children with SSNS during one year of follow-up. 
Publication Details
Page(s) 66-70
DOI DOI not available
Published Journal: Khyber Medical University Journal, Volume: 13, Issue: 2, Year: 2021

Request the full text from PASTIC

Keywords
Child, Preschool (MeSH), Relapse (MeSH), Nephrotic Syndrome (MeSH), Leukotriene Antagonists (MeSH), Child (MeSH), Recurrence (MeSH), Steroids (MeSH), Montelukast (MeSH)
0

Citations

0

Downloads

40

Views